Main > > >ASTHMA. *

---

Allergy>Asthma. TREAT.: OmalizuMAb for SubCutaneous Use.
Mechanism: Anti-IgE MAb
USA Approval >12 Years : 2003.
USA Approval 06-11 Years: 2016. 07.07.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 04.01




Bronchospasm. Prevention & Reversal: Terbutaline Sulfate Tablets. Generic.
USA Launch Date: 2018. 10.16.
(*) Company: ANI Pharma.
UpDate: 2018. 10.17.




TREAT.: Fluticasone Propionate and Salmeterol Inhalation Powder. Generic.
USA Approval Date: 2019. 01.30.
USA Launch Date: 2019. 02.12.
(*) Company: Mylan.
UpDate: 2019. 02.13.




TREAT.: OmalizuMAb for SubCutaneous Use.
See Also "Allergy"
Mechanism: Anti-IgE MAb
USA Approval >12 Years : 2003.
USA Approval 06-11 Years: 2016. 07.07.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 04.01




>ASTHMA. *'s products
This section has no products